Safety and Effectiveness of VYC-17.5L for Long-Term Correction of Nasolabial Folds

• Published in: Aesthetic surgery journal 2020-06, Vol.40 (7), p.767-777
• Main Authors: Dayan, Steven, Maas, Corey S, Grimes, Pearl E, Beer, Kenneth, Monheit, Gary, Snow, Sean, Murphy, Diane K, Lin, Vince
• Format: Article
• Language: English
• Subjects: Cosmetic Techniques - adverse effects; Humans; Hyaluronic Acid; Nasolabial Fold; Patient Satisfaction; Prospective Studies; Skin Aging; Treatment Outcome
• ISSN: 1090-820X; 1527-330X
• DOI: 10.1093/asj/sjz200

Juvéderm Vollure XC (VYC-17.5L; Allergan plc, Dublin, Ireland) belongs to a family of hyaluronic acid gels based on the Vycross technology platform. The authors sought to evaluate the safety and effectiveness of Vollure for correction of moderate to severe nasolabial folds (NLFs) over 18 months and after repeat treatment. In this prospective, randomized study, patients (N = 123) received initial/touch-up treatment with Vollure in 1 NLF and control filler in the contralateral NLF. Patients received optional repeat treatment with Vollure after month 12, 15, or 18. Assessments included investigator-rated NLF Severity Scale responder rates (≥1-point improvement vs baseline), patient-assessed Appraisal of Nasolabial Folds scale of the FACE-Q questionnaire, and patient satisfaction (11-point scale). Median volume of Vollure injected was 1.7 mL for initial/touch-up treatment combined and 0.6 mL for repeat treatment. The NLF Severity Scale responder rates were 93%, 85%, and 59% at months 6, 9, and 18 after initial/touch-up treatment and increased to 94% at 1 month after repeat treatment. Mean patient-reported FACE-Q scores significantly improved from baseline at all timepoints. Most patients were very satisfied with treatment at all timepoints from day 3 (75%) through month 18 (68%) and at 1 month after repeat treatment (94%). Common injection site responses after initial/touch-up and repeat treatment were firmness, swelling, and tenderness to touch; most were mild/moderate. Vollure was safe and effective for correction of moderate to severe NLFs, with results lasting 18 months in 59% of NLFs. Repeat treatment required one-third of the injection volume to achieve similar improvement in NLF severity as initial/touch-up treatment.